← Back to Screener
Apollomics Inc. Class A Ordinary Shares (APLM)
Price$13.53
Favorite Metrics
Price vs S&P 500 (26W)112.94%
Price vs S&P 500 (4W)-38.21%
Market Capitalization$15.34M
All Metrics
Book Value / Share (Quarterly)$4.41
P/TBV (Annual)3.44x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$7.60
Price vs S&P 500 (YTD)-28.91%
EPS (TTM)$-64.31
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$-64.31
EPS (Annual)$-52.80
ROI (Annual)-923.81%
Cash / Share (Quarterly)$1.90
ROA (Last FY)-411.19%
EBITD / Share (TTM)$-62.84
Cash Flow / Share (Annual)$-26.09
P/B Ratio3.15x
P/B Ratio (Quarterly)2.21x
Net Income / Employee (Annual)$-4
ROA (TTM)-549.50%
EPS Incl Extra (Annual)$-52.80
Current Ratio (Annual)1.39x
Quick Ratio (Quarterly)0.89x
3-Month Avg Trading Volume0.02M
52-Week Price Return-91.47%
Tangible BV / Share (Quarterly)$2.84
52-Week High$42.12
EPS Excl Extra (Annual)$-52.80
26-Week Price Return121.69%
Quick Ratio (Annual)1.32x
13-Week Price Return-36.09%
Total Debt / Equity (Annual)0.20x
Current Ratio (Quarterly)0.97x
Enterprise Value$13.987
Revenue / Employee (Annual)$0
Cash / Share (Annual)$8.86
3-Month Return Std Dev73.24%
Net Income / Employee (TTM)$-5
ROE (Last FY)-1107.28%
EPS Basic Excl Extra (Annual)$-52.80
EV / Free Cash Flow (TTM)1.67x
Total Debt / Equity (Quarterly)0.20x
EPS Incl Extra (TTM)$-64.31
ROI (TTM)-567.60%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.84
Price vs S&P 500 (52W)-92.51%
Year-to-Date Return-25.65%
5-Day Price Return2.21%
EPS Normalized (Annual)$-52.80
Month-to-Date Return-12.30%
Cash Flow / Share (TTM)$-0.02
EBITD / Share (Annual)$-53.04
LT Debt / Equity (Annual)0.00x
P/CF (TTM)1.83x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-64.31
P/TBV (Quarterly)3.44x
P/B Ratio (Annual)2.21x
Book Value / Share (Annual)$4.41
Price vs S&P 500 (13W)-38.96%
Beta1.45x
ROE (TTM)-693.39%
52-Week Low$3.66
Analyst Recommendations
Sep 2024
Oct 2024
Nov 2024
Dec 2024
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
APLMApollomics Inc. Class A Ordinary Shares | — | — | — | — | $13.53 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Apollomics is a clinical-stage biopharmaceutical company developing oncology therapies designed to enhance immune function and target specific molecular pathways. The company's lead programs include vebreltinib (APL-101), a c-Met inhibitor for non-small cell lung cancer and other c-Met-altered tumors, and uproleselan (APL-106), an E-Selectin antagonist being evaluated in combination with chemotherapy for acute myeloid leukemia.